- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
NHL Treatment Market Boom Will Be Hindered in EU
The global non-hodgkin lymphoma (NHL) treatment market will increase in value from $5.6 billion in 2013 to $9.2 billion by 2020, according to GBI Research.
The global non-hodgkin lymphoma (NHL) treatment market will increase in value from $5.6 billion in 2013 to $9.2 billion by 2020, according to GBI Research.
The company says that high unmet clinical needs and the launch of promising drugs will be key global drivers, although the patent expiry of blockbuster Rituxan in the EU will hinder market growth in this region.
GBI Research analyst Sravanthi Addapally says that while Rituxan has dramatically improved NHL patient prognosis and been the standard of care in front-line treatment regimens, there is increasing evidence of resistance to the drug. Overcoming this has been a major focus of recent therapeutic development. This treatment challenge will create space for the entry of three promising new therapies, which will ultimately drive NHL market growth.
“The second generation anti-CD20 monoclonal Antibody, ofatumumab, and the third generation anti-CD20 mAb, obinutuzumab, may be able to induce stronger complement-dependent cytotoxicity in rituximab-resistant cell lines. Additionally, the immunotherapeutic vaccine dasiprotimut-T has the potential to eliminate the risk of rituximab resistance,” says Addapally.
While Rituxan, or Mabthera “is expected to retain its superior share of the NHL treatment space, the cost decrease following the drug’s patent expiry will be the prime reason for the flat market in the EU.”
Further information can be found on the GBI Research website.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Seeking Sustainable Solutions: Can Passion and Profit Coexist in Pharma ESG Efforts?
October 15th 2024Industry leaders gather to discuss different ways life sciences organizations can champion their environmentally-conscious younger employees while combatting still-entrenched public mistrust.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
